HOME >> BIOLOGY >> NEWS
Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune ,,disease and cancer

FREMONT, CALIF., December 1, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has signed a research license and option agreement with Chiron, Inc. ("Chiron") (Nasdaq: CHIR) under which Chiron will use Abgenix's XenoMouse™ technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of autoimmune diseases. In return, Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales by Chiron. Under a separate research collaboration agreement, Chiron may use XenoMouse to generate fully human monoclonal antibodies on up to four cancer targets. Chiron will be responsible for product development, manufacturing, and marketing of any products developed through the collaboration.

"We are delighted to be working with Chiron, one of the world's leading biotechnology companies," stated R. Scott Greer, president and CEO of Abgenix. "Chiron becomes the fourteenth partner using our XenoMouse technology to generate antibody product candidates. This deal also represents the eighth new potential product candidate being pursued by one of our XenoMouse collaborators this year."

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease and cancer. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials.


'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
5. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Chiron reports on discovery of novel men B vaccine candidates based on whole genome sequencing of Neisseria meningitidis by TIGR
8. Chiron Discovers Significant Hepatitis C Binding Mechanism; Data Indicates CD81 Protein May Be A Virus Receptor
9. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
10. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
11. New Arizona State center brings science to policy on issues of water resources and urban growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
Breaking Biology Technology:
Cached News: